CENTRE HOSPITALIER UNIVERSITAIRE DE DIJON
🇫🇷France
Clinical Trials
492
Active:9
Completed:261
Trial Phases
5 Phases
Phase 1:20
Phase 2:18
Phase 3:32
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (244 trials with phase data)• Click on a phase to view related trials
Not Applicable
156 (63.9%)Phase 3
32 (13.1%)Phase 1
20 (8.2%)Phase 2
18 (7.4%)Phase 4
17 (7.0%)phase_1_2
1 (0.4%)The Benefits of Virtual Reality in the Care of Elderly People With Psychomotor Disadaptation Syndrome
Not Applicable
Not yet recruiting
- Conditions
- Psychomotor Disadaptation Syndrome
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 50
- Registration Number
- NCT07026890
Study of the Impact of HYPOglycaemia on Sarcopenia in CIRrhosis
Not yet recruiting
- Conditions
- Cirrhosis
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 200
- Registration Number
- NCT06948656
- Locations
- 🇫🇷
CHU Dijon Bourgogne, Dijon, France
POlycythemia, Proteins and ErYthropoiesis
Recruiting
- Conditions
- Erythropoiesis
- Interventions
- Biological: Collection of tube bottoms from blood samples taken in the clinic
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 400
- Registration Number
- NCT06905106
- Locations
- 🇫🇷
CHU Dijon Bourgogne, Dijon, France
A Pilot Study to Assess the Feasibility and Acceptability of Newborn Screening Using in Silico Panel-based Solo Genome Sequencing in France
Recruiting
- Conditions
- Newborn Screening Programmes for Rare Diseases
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 5000
- Registration Number
- NCT06875089
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHU Besançon, Besançon, France
🇫🇷CHU Dijon Bourgogne, Dijon, France
PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Ampullary Adenocarcinoma
- Interventions
- Drug: mFOLFORINOXDrug: Capecitabine or gemcitabineBiological: Biological assessmentDiagnostic Test: Paraclinical examinations
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 294
- Registration Number
- NCT06813976
- Locations
- 🇫🇷
CHU Dijon Bourgogne, Dijon, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 95
- Next
News
No news found